인도의 약물전달 기기 : 시장 점유율 분석, 산업 동향, 통계, 성장 예측(2025-2030년)

The India drug delivery devices market is valued at USD 6.88 billion in 2025 and is expected to reach USD 11.56 billion by 2030, reflecting a 10.93% CAGR through the forecast period.

Expanding healthcare infrastructure, a sharp rise in chronic disease prevalence, and policy support for domestic production are driving sustained demand for advanced therapeutic platforms. Continued government funding under the Production Linked Incentive scheme and fast-track regulatory pathways have lowered barriers for novel devices, particularly in injectables and connected systems. Manufacturers are also benefiting from the National Medical Devices Policy 2023, which aligns standards with global norms and fosters local innovation clusters in Gujarat, Maharashtra, Tamil Nadu, and Himachal Pradesh. Persistent cost pressures in India's predominantly out-of-pocket healthcare market have pushed suppliers to develop value-oriented, user-friendly technologies that can safely transition from hospital to home settings.

India Drug Delivery Devices Market Trends and Insights

Government Initiatives To Support Healthcare Access

Public spending on health rose to INR 89,287 crore in the 2024-25 Union Budget, channeling capital into primary care and device procurement within Tier 2 and Tier 3 cities. A streamlined approval pathway under the National Medical Devices Policy 2023 now accelerates clearances for injectable and implantable systems, cutting previous timelines by nearly one-third. Coupled with the Export Promotion Council for Medical Devices established in 2025, local firms gain faster export certifications and market entry support. These policy moves have widened adoption of affordable autoinjectors in semi-urban hospitals, fueling incremental demand across the India drug delivery devices market. Increased funding further supports clinical validation studies, ensuring new domestic products meet international standards.

High Demand for Cost-Effective Drugs Such as Biosimilars

Indian biosimilar producers, led by Biocon and Dr. Reddy's, have launched low-cost versions of biologics that require dedicated delivery formats. Biocon's generic liraglutide received clearance in 2024, triggering higher volumes of reusable pens designed for multi-dose regimens. As 15 additional peptide formulations near approval, demand has surged for compact autoinjectors configured for subcutaneous delivery in home settings. Urban adoption is especially strong, where clinicians now prescribe biosimilars to lower total treatment expenses, thereby expanding penetration of connected pens that upload dosing data to electronic medical records. The virtuous cycle between biosimilar growth and device innovation strengthens competitiveness of domestic firms in the India drug delivery devices market.

High Out-of-Pocket Spending Restricting Adoption of Advanced Implantable Systems

Out-of-pocket payments still make up 55% of India's total health expenditure, limiting access to implantable pumps that cost USD 2,000-5,000 each. Reimbursement remains patchy outside large private insurers, pushing many patients toward lower-cost external pumps or conventional syringes. Uptake therefore concentrates in metro hospitals, creating uneven distribution across the India drug delivery devices market. Government plans to expand Pradhan Mantri Jan Arogya Yojana coverage to implantable drug platforms could ease this constraint, yet short-term adoption remains capped by affordability gaps in rural districts.

Other drivers and restraints analyzed in the detailed report include:

1. High Burden of Chronic and Infectious Diseases Coupled with Aging Population
2. Government and Market Players Initiatives for Boosting Domestic Manufacturing of Medical Devices
3. Regulatory Uncertainty Around Classification of Combination Products Causing Approval Delays

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Injectable delivery devices represented 45.0% of the India drug delivery devices market in 2024, reflecting high demand for pens, autoinjectors, and safety syringes across diabetes, oncology, and immunology care. Prefilled syringes minimize handling errors, while spring-loaded autoinjectors improve self-administration, particularly for aging patients who face dexterity challenges. Growing acceptance of biosimilars has expanded volume requirements for low-dead-space syringe formats and reusable pen platforms. Hospitals remain the largest customers, yet pharmacies increasingly dispense self-use devices, spurring retail distribution models.

Implantable devices are on track for a 12.04% CAGR to 2030. Materials such as titanium alloys and bioresorbable polymers provide controlled release for analgesics, antispasmodics, and neuroactive compounds. Deep-brain pumps demonstrate promise for Parkinson's and epilepsy, with early clinical data showing sustained symptom control and lower systemic exposure. Domestic startups collaborate with IITs to refine miniaturized energy sources, aligning with Make-in-India objectives. As procurement costs fall, implantables will capture higher revenue share within the broader India drug delivery devices market size projections.

The injectable route held a 50.0% share of the India drug delivery devices market size in 2024, supported by biologicals that cannot be delivered orally. Smart pens store dosing logs, forwarding encrypted records to clinicians, and enable early detection of non-adherence. Cold-chain innovations, such as phase-change packaging, safeguard product integrity during last-mile delivery, widening geographic reach.

Nasal delivery is moving at an 11.45% CAGR through 2030. Mucoadhesive gels and surfactant-enhanced sprays improve drug absorption and can traverse the olfactory epithelium to reach the brain. Focus areas include migraine, Alzheimer's, and even needle-free vaccine boosters. Indian firms license membrane-permeation enhancers, shortening development cycles. Pilot programs in tertiary hospitals show strong patient preference for nasal therapies, likely to boost future India drug delivery devices market share in central nervous system indications.

The India Drug Delivery Devices Market is Segmented by Device Type (Injectable Delivery Devices, Inhalation Delivery Devices, Infusion Pumps, and More), Route of Administration (Injectable, Inhalational, Trandermal and More), and Application (Cancer, Cardiovascular Diseases, Diabetes and More), End User (Hospitals, Ambulatory Surgical Centers and More). The Market and Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

1. Sanofi
2. Becton, Dickinson and Company (BD) India
3. Cipla
4. Novo Nordisk India Pvt Ltd
5. Sun Pharmaceuticals Industries
6. Biocon Ltd
7. Dr. Reddy's Laboratories Ltd
8. Lupin
9. Meril Life Sciences
10. Zydus Lifesciences Ltd
11. Medtronic
12. Terumo India Pvt Ltd
13. Baxter India Pvt Ltd
14. B. Braun Medical (India) Pvt Ltd
15. Ysomed
16. Bayer
17. Pfizer Ltd (India)
18. Johnson & Johnson Pvt Ltd (Janssen)
19. Roche Products (India) Pvt Ltd
20. Abbott India Ltd

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Government Initiatives To Support Healthcare Access
  • 4.2.2 High Demand for Cost Effective Drugs Such as Biosimiliar
  • 4.2.3 High Burden of Chrnoic and Infectious Diseases Coupled with Aging Population
  • 4.2.4 Government and Market Players Initiatitives for Boosting Domestic Manufacruring of Medical Devices
  • 4.2.5 Technological Advancement and Increased Awareness for Smart/ Connected Drug Delivery Devices
  • 4.2.6 Rapid Expansion of Home-care and Tele-medicine Models Encouraging Self-administration Devices
• 4.3 Market Restraints
  • 4.3.1 High Out-of-Pocket Spending Restricting Adoption of Advanced Implantable Systems
  • 4.3.2 Regulatory Uncertainty Around Classification of Combination Products Causing Approval Delays
  • 4.3.3 Skilled Healthcare Professional Shortage in Tier-2/3 Cities Impeding Safe Use of Infusion Pumps
  • 4.3.4 Fragmented Cold-chain Logistics Limiting Reach of Temperature-Sensitive Injectable Devices
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory and Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers/Consumers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitute Products
  • 4.6.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

• 5.1 By Device Type
  • 5.1.1 Injectable Delivery Devices
  • 5.1.2 Inhalation Delivery Devices
  • 5.1.3 Infusion Pumps
  • 5.1.4 Transdermal Patches
  • 5.1.5 Implantable Drug Delivery Systems
  • 5.1.6 Ocular Inserts and Delivery Implants
  • 5.1.7 Nasal & Buccal Delivery Devices
• 5.2 By Route of Administration
  • 5.2.1 Injectable
  • 5.2.2 Inhalation
  • 5.2.3 Transdermal
  • 5.2.4 Oral Mucosal (Buccal and Sublingual)
  • 5.2.5 Ocular
  • 5.2.6 Nasal
• 5.3 By Application
  • 5.3.1 Cancer
  • 5.3.2 Cardiovascular Diseases
  • 5.3.3 Diabetes
  • 5.3.4 Respiratory and Infectious Diseases
  • 5.3.5 Neurological Disorders
  • 5.3.6 Others
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Ambulatory Surgical Centers
  • 5.4.3 Home Healthcare Settings
  • 5.4.4 Clinics and Others

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Strategic Moves
• 6.3 Market Share Analysis
• 6.4 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.4.1 Sanofi
  • 6.4.2 Becton, Dickinson and Company (BD) India
  • 6.4.3 Cipla Ltd
  • 6.4.4 Novo Nordisk India Pvt Ltd
  • 6.4.5 Sun Pharmaceutical Industries Ltd
  • 6.4.6 Biocon Ltd
  • 6.4.7 Dr. Reddy's Laboratories Ltd
  • 6.4.8 Lupin Ltd
  • 6.4.9 Meril Life Sciences
  • 6.4.10 Zydus Lifesciences Ltd
  • 6.4.11 Medtronic Plc
  • 6.4.12 Terumo India Pvt Ltd
  • 6.4.13 Baxter India Pvt Ltd
  • 6.4.14 B. Braun Medical (India) Pvt Ltd
  • 6.4.15 Ysomed
  • 6.4.16 Bayer Pharmaceuticals India Ltd
  • 6.4.17 Pfizer Ltd (India)
  • 6.4.18 Johnson & Johnson Pvt Ltd (Janssen)
  • 6.4.19 Roche Products (India) Pvt Ltd
  • 6.4.20 Abbott India Ltd

7 Market Opportunities and Future Outlook

• 7.1 White-space and Unmet-Need Assessment